Opinion|Videos|July 15, 2024
Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.
Advertisement
Episodes in this series
- In which patients may you consider 1L doublet therapy (VEN + BTKi) or triplet therapy? How do available data inform your treatment decision?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
4
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
5